Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Characterization and Validation of Antibodies for Immunohistochemical Staining of the Chemokine CXCL12.

Fricker SP, Sprott K, Spyra M, Uhlig P, Lange N, David K, Wang Y.

J Histochem Cytochem. 2019 Apr;67(4):257-266. doi: 10.1369/0022155418818788. Epub 2018 Dec 18.

2.

Targeting chemokine receptors for HIV: past, present and future.

Fricker SP.

Future Med Chem. 2015;7(17):2311-5. doi: 10.4155/fmc.15.153. Epub 2015 Dec 2. No abstract available.

PMID:
26627446
3.

Specificity for a CCR5 Inhibitor Is Conferred by a Single Amino Acid Residue: ROLE OF ILE198.

Lau G, Labrecque J, Metz M, Vaz R, Fricker SP.

J Biol Chem. 2015 Apr 24;290(17):11041-51. doi: 10.1074/jbc.M115.640169. Epub 2015 Mar 12.

4.

CXCRâ‚„antagonism as a therapeutic approach to prevent acute kidney injury.

Zuk A, Gershenovich M, Ivanova Y, MacFarland RT, Fricker SP, Ledbetter S.

Am J Physiol Renal Physiol. 2014 Oct 1;307(7):F783-97. doi: 10.1152/ajprenal.00685.2013. Epub 2014 Jul 30.

5.

Chemokine receptor modeling: an interdisciplinary approach to drug design.

Fricker SP, Metz M.

Future Med Chem. 2014 Jan;6(1):91-114. doi: 10.4155/fmc.13.194. Review.

PMID:
24358950
6.

Physiology and pharmacology of plerixafor.

Fricker SP.

Transfus Med Hemother. 2013 Aug;40(4):237-45. doi: 10.1159/000354132. Epub 2013 Jul 19. Review.

7.

Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070.

O'Boyle G, Swidenbank I, Marshall H, Barker CE, Armstrong J, White SA, Fricker SP, Plummer R, Wright M, Lovat PE.

Br J Cancer. 2013 Apr 30;108(8):1634-40. doi: 10.1038/bjc.2013.124. Epub 2013 Mar 28.

8.

The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor.

Mosi RM, Anastassova V, Cox J, Darkes MC, Idzan SR, Labrecque J, Lau G, Nelson KL, Patel K, Santucci Z, Wong RS, Skerlj RT, Bridger GJ, Huskens D, Schols D, Fricker SP.

Biochem Pharmacol. 2012 Feb 15;83(4):472-9. doi: 10.1016/j.bcp.2011.11.020. Epub 2011 Nov 28.

PMID:
22146583
9.

Prospective CCR5 small molecule antagonist compound design using a combined mutagenesis/modeling approach.

Metz M, Bourque E, Labrecque J, Danthi SJ, Langille J, Harwig C, Yang W, Darkes MC, Lau G, Santucci Z, Bridger GJ, Schols D, Fricker SP, Skerlj RT.

J Am Chem Soc. 2011 Oct 19;133(41):16477-85. doi: 10.1021/ja2043722. Epub 2011 Sep 23.

PMID:
21942640
10.

Strategies for the biological evaluation of gold anticancer agents.

Fricker SP.

Anticancer Agents Med Chem. 2011 Dec;11(10):940-52. Review.

PMID:
21864236
11.

Antitumor actions of ruthenium(III)-based nitric oxide scavengers and nitric oxide synthase inhibitors.

Flitney FW, Pritchard RJ, Kennovin GD, Bisland SK, Hirst DG, Fricker SP.

Mol Cancer Ther. 2011 Sep;10(9):1571-80. doi: 10.1158/1535-7163.MCT-10-0840. Epub 2011 Jun 28.

12.

Inhibition of the cathepsin cysteine proteases B and K by square-planar cycloaurated gold(III) compounds and investigation of their anti-cancer activity.

Zhu Y, Cameron BR, Mosi R, Anastassov V, Cox J, Qin L, Santucci Z, Metz M, Skerlj RT, Fricker SP.

J Inorg Biochem. 2011 May;105(5):754-62. doi: 10.1016/j.jinorgbio.2011.01.012. Epub 2011 Jan 26.

PMID:
21481817
13.

HIV-1 entry inhibition by small-molecule CCR5 antagonists: a combined molecular modeling and mutant study using a high-throughput assay.

Labrecque J, Metz M, Lau G, Darkes MC, Wong RS, Bogucki D, Carpenter B, Chen G, Li T, Nan S, Schols D, Bridger GJ, Fricker SP, Skerlj RT.

Virology. 2011 May 10;413(2):231-43. doi: 10.1016/j.virol.2011.02.016. Epub 2011 Mar 9.

14.

Cysteine proteases as targets for metal-based drugs.

Fricker SP.

Metallomics. 2010 Jun;2(6):366-77. doi: 10.1039/b924677k. Epub 2010 May 7. Review.

PMID:
21072382
15.

CXCL12 (SDF-1)/CXCR4 pathway in cancer.

Teicher BA, Fricker SP.

Clin Cancer Res. 2010 Jun 1;16(11):2927-31. doi: 10.1158/1078-0432.CCR-09-2329. Epub 2010 May 18. Review.

16.

Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4.

Bodart V, Anastassov V, Darkes MC, Idzan SR, Labrecque J, Lau G, Mosi RM, Neff KS, Nelson KL, Ruzek MC, Patel K, Santucci Z, Scarborough R, Wong RS, Bridger GJ, Macfarland RT, Fricker SP.

Biochem Pharmacol. 2009 Oct 15;78(8):993-1000. doi: 10.1016/j.bcp.2009.06.010. Epub 2009 Jun 18.

PMID:
19540208
17.

A time-resolved fluorescent lanthanide (Eu)-GTP binding assay for chemokine receptors as targets in drug discovery.

Labrecque J, Wong RS, Fricker SP.

Methods Mol Biol. 2009;552:153-69. doi: 10.1007/978-1-60327-317-6_11.

PMID:
19513648
18.

A novel CXCR4 antagonist for hematopoietic stem cell mobilization.

Fricker SP.

Expert Opin Investig Drugs. 2008 Nov;17(11):1749-60. doi: 10.1517/13543784.17.11.1749 . Review.

PMID:
18922110
19.

Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors.

Wong RS, Bodart V, Metz M, Labrecque J, Bridger G, Fricker SP.

Mol Pharmacol. 2008 Dec;74(6):1485-95. doi: 10.1124/mol.108.049775. Epub 2008 Sep 2.

PMID:
18768385
20.

Metal compounds for the treatment of parasitic diseases.

Fricker SP, Mosi RM, Cameron BR, Baird I, Zhu Y, Anastassov V, Cox J, Doyle PS, Hansell E, Lau G, Langille J, Olsen M, Qin L, Skerlj R, Wong RS, Santucci Z, McKerrow JH.

J Inorg Biochem. 2008 Oct;102(10):1839-45. doi: 10.1016/j.jinorgbio.2008.05.010. Epub 2008 Jun 4. Erratum in: J Inorg Biochem. 2009 May;103(5):869.

PMID:
18684510
21.

A Screening Strategy for Metal Antitumor Agents as Exemplified by Gold(III) Complexes.

Fricker SP.

Met Based Drugs. 1999;6(4-5):291-300. doi: 10.1155/MBD.1999.291.

22.

Metal based drugs: from serendipity to design.

Fricker SP.

Dalton Trans. 2007 Nov 21;(43):4903-17. Epub 2007 Sep 19. Review.

PMID:
17992275
23.

Rhenium inhibitors of cathepsin B (ReO(SYS)X (where Y = S, py; X = Cl, Br, SPhOMe-p)): Synthesis and mechanism of inhibition.

Mosi R, Baird IR, Cox J, Anastassov V, Cameron B, Skerlj RT, Fricker SP.

J Med Chem. 2006 Aug 24;49(17):5262-72.

PMID:
16913715
24.

AMD3465, a novel CXCR4 receptor antagonist, abrogates schistosomal antigen-elicited (type-2) pulmonary granuloma formation.

Hu JS, Freeman CM, Stolberg VR, Chiu BC, Bridger GJ, Fricker SP, Lukacs NW, Chensue SW.

Am J Pathol. 2006 Aug;169(2):424-32.

25.

Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4.

Fricker SP, Anastassov V, Cox J, Darkes MC, Grujic O, Idzan SR, Labrecque J, Lau G, Mosi RM, Nelson KL, Qin L, Santucci Z, Wong RS.

Biochem Pharmacol. 2006 Aug 28;72(5):588-96. Epub 2006 Jul 3.

PMID:
16815309
26.

The therapeutic application of lanthanides.

Fricker SP.

Chem Soc Rev. 2006 Jun;35(6):524-33. Epub 2006 Apr 28. Review.

PMID:
16729146
27.

The development of an europium-GTP assay to quantitate chemokine antagonist interactions for CXCR4 and CCR5.

Labrecque J, Anastassov V, Lau G, Darkes M, Mosi R, Fricker SP.

Assay Drug Dev Technol. 2005 Dec;3(6):637-48.

PMID:
16438659
28.

The ruthenium-based nitric oxide scavenger, AMD6221, augments cardiovascular responsiveness to noradrenaline in rats with streptozotocin-induced diabetes.

Hutchings SR, Song D, Fricker SP, Pang CC.

Eur J Pharmacol. 2005 Dec 28;528(1-3):132-6. Epub 2005 Nov 28.

PMID:
16310182
29.

Nitric oxide scavengers as a therapeutic approach to nitric oxide mediated disease.

Fricker SP.

Expert Opin Investig Drugs. 1999 Aug;8(8):1209-22.

PMID:
15992146
30.

Biology of Nitric Oxide 6th International Meeting.

Fricker SP.

Expert Opin Investig Drugs. 1999 Dec;8(12):2225-31. No abstract available.

PMID:
15992064
31.

Ruthenium as an effective nitric oxide scavenger.

Marmion CJ, Cameron B, Mulcahy C, Fricker SP.

Curr Top Med Chem. 2004;4(15):1585-603. Review.

PMID:
15579098
32.

Metal complexes as therapeutic agents in nitrogen monoxide modulation.

Fricker SP.

Met Ions Biol Syst. 2004;41:421-80. Review. No abstract available.

PMID:
15206124
33.

Ruthenium(III) triazacyclononane dithiocarbamate, pyridinecarboxylate, or aminocarboxylate complexes as scavengers of nitric oxide.

Cameron BR, Darkes MC, Baird IR, Skerlj RT, Santucci ZL, Fricker SP.

Inorg Chem. 2003 Jun 30;42(13):4102-8.

PMID:
12817968
34.

Ruthenium(III) polyaminocarboxylate complexes: efficient and effective nitric oxide scavengers.

Cameron BR, Darkes MC, Yee H, Olsen M, Fricker SP, Skerlj RT, Bridger GJ, Davies NA, Wilson MT, Rose DJ, Zubieta J.

Inorg Chem. 2003 Mar 24;42(6):1868-76.

PMID:
12639119
35.

Mechanistic studies on AMD6221: a ruthenium-based nitric oxide scavenger.

Mosi R, Seguin B, Cameron B, Amankwa L, Darkes MC, Fricker SP.

Biochem Biophys Res Commun. 2002 Mar 29;292(2):519-29.

PMID:
11906192
36.

A ruthenium (III) polyaminocarboxylate complex, a novel nitric oxide scavenger, enhances graft survival and decreases nitrosylated heme protein in models of acute and delayed cardiac transplant rejection.

Pieper GM, Roza AM, Adams MB, Hilton G, Johnson M, Felix CC, Kampalath B, Darkes M, Wanggui Y, Cameron B, Fricker SP.

J Cardiovasc Pharmacol. 2002 Mar;39(3):441-8.

PMID:
11862124
37.

A novel scavenger of nitric oxide decreases heme protein nitrosylation and prolongs graft survivial during cardiac transplant rejection.

Pieper GM, Roza AM, Adams MB, Johnson M, Hilton G, Felix CC, Fricker SP.

J Heart Lung Transplant. 2001 Feb;20(2):157. No abstract available.

PMID:
11250230
38.

The in vitro antitumour profile of some 1,2-diaminocyclohexane organotin complexes.

Bonire JJ, Fricker SP.

J Inorg Biochem. 2001 Jan 15;83(2-3):217-21.

PMID:
11237262
39.

Biology, chemistry and therapeutic applications of nitric oxide: First International Conference.

Fricker SP.

Expert Opin Investig Drugs. 2000 Oct;9(10):2411-7. No abstract available.

PMID:
11203288
40.

Metal complexes of bleomycin: evaluation of [Rh-105]-bleomycin for use in targeted radiotherapy.

Brooks RC, Carnochan P, Vollano JF, Powell NA, Zweit J, Sosabowski JK, Martellucci S, Darkes MC, Fricker SP, Murrer BA.

Nucl Med Biol. 1999 May;26(4):421-30.

PMID:
10382846
41.

Macrophage-derived superoxide is not required for nitric oxide mediated tumour cell killing by RAW 264 cells.

Fricker SP, Slade E, Powell NA.

Anticancer Res. 1999 Jan-Feb;19(1A):553-6.

PMID:
10226597
42.

Nitrogen monoxide-related disease and nitrogen monoxide scavengers as potential drugs.

Fricker SP.

Met Ions Biol Syst. 1999;36:665-721. Review. No abstract available.

PMID:
10093939
43.

Ruthenium complexes as nitric oxide scavengers: a potential therapeutic approach to nitric oxide-mediated diseases.

Fricker SP, Slade E, Powell NA, Vaughan OJ, Henderson GR, Murrer BA, Megson IL, Bisland SK, Flitney FW.

Br J Pharmacol. 1997 Dec;122(7):1441-9.

44.

Antitumor properties of some 2-[(dimethylamino)methyl]phenylgold(III) complexes.

Buckley RG, Elsome AM, Fricker SP, Henderson GR, Theobald BR, Parish RV, Howe BP, Kelland LR.

J Med Chem. 1996 Dec 20;39(26):5208-14.

PMID:
8978849
45.
46.

Chemical and Biological Studies of Dichloro(2-((dimethylamino)methyl)phenyl)gold(III).

Parish RV, Howe BP, Wright JP, Mack J, Pritchard RG, Buckley RG, Elsome AM, Fricker SP.

Inorg Chem. 1996 Mar 13;35(6):1659-1666.

PMID:
11666388
47.

Effect of superoxide dismutase on nitric oxide production by RAW264 macrophages.

Fricker SP, Slade E, Powell NA.

Biochem Soc Trans. 1995 May;23(2):231S. No abstract available.

PMID:
7545607
48.
50.

Supplemental Content

Loading ...
Support Center